CAJ | 학술논문

目的评价盐酸尼莫司汀与替尼泊苷联合化疗方案对恶性脑神经胶质瘤的治疗效果和不良反应.方法选择合格病例38例,随机分为两组:实验组(18例)为盐酸尼莫司汀加替尼泊苷(NV)组,2～6个周期;对照组(20例)为司莫司汀加替尼泊苷(SV)组,2～6个周期.第1周期化疗后同步行常规局部外放疗.结果 38例患者有效26例,其中实验组14例有效,对照组12例有效;经X2检验,两种化疗方案有效率差异无统计学意义.两组主要不良反应均为骨髓抑制,特别是中性粒细胞减少.病人每2个月随访1次.1年生存率:NV组为72%(13/18);SV组为65%(13/20);两组比较差异无统计学意义(P=0.60).结论盐酸尼莫司汀与替尼泊苷联合化疗治疗恶性胶质瘤,安全、有效.为脑神经胶质瘤辅助化疗提供了新方案.
목적 평개염산니막사정여체니박감연합화료방안대악성뇌신경효질류적치료효과화불량반응.방법 선택합격병례38례,수궤분위량조:실험조(18례)위염산니막사정가체니박감(NV)조,2～6개주기;대조조(20례)위사막사정가체니박감(SV)조,2～6개주기.제1주기화료후동보행상규국부외방료.결과 38례환자유효26례,기중실험조14례유효,대조조12례유효;경X2검험,량충화료방안유효솔차이무통계학의의.량조주요불량반응균위골수억제,특별시중성립세포감소.병인매2개월수방1차.1년생존솔:NV조위72%(13/18);SV조위65%(13/20);량조비교차이무통계학의의(P=0.60).결론 염산니막사정여체니박감연합화료치료악성효질류,안전、유효.위뇌신경효질류보조화료제공료신방안.
Objective This study was designed to evaluate the efficacy and toxicity of nimustine and teniposide combination chemotherapy on malignant gliomas.Method Thirty-eight eligible patients were randomized into two groups.The chemotherapy regimen of the experimental group is NV(nimustine and teniposide),the control group is SV(semustine and teniposide).These patients also received the routine radiotherapy after the first cycle chemotherapy.Results Among 38 cases,18 patients belong to NV group and 20 patients belong to SV group.The effective rates of NV groups,SV groups arc 78%(14/18)and 60%(12/20),respectively.The dose-limiting toxicity is the bone marrow suppression,especially granulocytopenia.These patients were followed up with enhanced MRI every two months.The one-year survival rate wag 72%(13/18)and 65%(13/20),respectively(P=0.60).Conclusions It is a safe and effective therapeutic strategy of malignant gliomas by using NV combination chemotherapy regimen.